Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HINT1 | P49773 | 2/20 | 0.37 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.35 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15166247 | 1.00 | KDM4E (0.49) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL10068164 | 0.92 | KDM4E (0.55) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL15166036 | 0.92 | KDM4E (0.55) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL10067497 | 0.92 | KDM4E (0.55) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL15166032 | 0.89 | KDM4E (0.53) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL10067865 | 0.89 | KDM4E (0.63) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL15164161 | 0.89 | KDM4E (0.63) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL10068165 | 0.87 | KDM4E (0.59) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL10067718 | 0.86 | KDM4E (0.50) | KDM4EHINT1POLA1TAS1R3TAS1R1 | |
| SCHEMBL15164162 | 0.86 | KDM4E (0.50) | KDM4EHINT1POLA1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133231-B2 | Compounds for treating bacterial infections | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-09-15 | — | — | US | disclosed |
| US-20130203694-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| WO-2012017434-A2 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203694-A1 | COMPOUNDS FOR TREATING BACTERIAL INFECTIONS | REL, RELA, RRP1B | KDM4E 2841/4885HINT1 2636/4885POLA1 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.